NGD 4715

Drug Profile

NGD 4715

Alternative Names: NGD-4715

Latest Information Update: 11 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Class Obesity therapies
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 10 Jan 2008 Adverse events, efficacy and pharmacodynamics data from phase I, multiple-ascending dose (MAD) studies released by Neurogen Corporation
  • 08 Jan 2008 Discontinued - Phase-I for Obesity in USA (PO)
  • 07 May 2007 Clinical data added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top